# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis

> **NCT00848055** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 40 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** AbGn168 intravenous infusion
- **DRUG:** AbGn168 intravenous infusion
- **DRUG:** AbGn168 intravenous infusion
- **DRUG:** AbGn168 intravenous infusion
- **DRUG:** AbGn168 intravenous infusion
- **DRUG:** AbGn168 intravenous infusion
- **DRUG:** AbGn168 intravenous infusion
- **DRUG:** AbGn168 subcutaneous injection

## Key facts

- **NCT ID:** NCT00848055
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2010-10
- **Final completion:** —
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00848055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00848055, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00848055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*